Ladostigil

Ladostigil
IUPAC ime
	[(3R)-3-(prop-2-inilamino)indan-5-il]-N-propilkarbamat
Klinički podaci
Način primene	Oralno
Pravni status
Pravni status	Nije kontrolisan;
Identifikatori
CAS broj	209349-27-4
ATC kod	none
PubChem	CID 208907
ChemSpider	181005
UNII	SW3H1USR4Q
Sinonimi	[N-propargil-(3R)-aminoindan-5il]-N-propilkarbamat
Hemijski podaci
Formula	C16H20N2O2
Molarna masa	272,34 g/mol

Ladostigil (TV-3,326) je neuroprotektivni agens koji se istražuje za moguću primenu u lečenju neurodegenerativnih poremećaja poput Alchajmerove bolesti, demencije sa Levijevim telima, i Parkinsonove bolesti.^[1] On deluje kao reversiblni inhibitor acetilholinesteraze i butirilholinesteraze, i kao ireverzibilni inhibitor monoamiske oksidaze B. On kombinuje mehanizme dejstva starijih lekova kao što su rivastigmin i rasagilin u jedan molekul.^[2]^[3] Osim neuroprotektivnih svojstava, ladostigil poboljšava izražavanje neurotrofnih faktora poput GDNF i BDNF, a moguće je da ima sposobnost povraćanja dela oštećenja prisutnih kod neurodegenerativnih bolesti putem indukcije neutrogeneze.^[4] Ladostigil takođe ima antidepresivno dejstvo, i može da bude koristan pri lečenju depresije i anksioznosti.^[5]^[6]

Reference

^ Weinstock, M.; Bejar, C.; Wang, R. H.; et al. (2000). „TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease”. Journal of Neural Transmission. Supplementum (60): 157—69. ISBN 978-3-211-83537-1. PMID 11205137. doi:10.1007/978-3-7091-6301-6_10.
^ Weinreb, O.; Mandel, S.; Bar-Am O; et al. (2009). „Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs”. Neurotherapeutics : The Journal of the American Society for Experimental NeuroTherapeutics. 6 (1): 163—74. PMC 5084264 . PMID 19110207. doi:10.1016/j.nurt.2008.10.030.
^ Weinstock M, Luques L, Bejar C, Shoham S (2006). „Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression”. Journal of Neural Transmission. Supplementum (70): 443—6. ISBN 978-3-211-28927-3. PMID 17017566. doi:10.1007/978-3-211-45295-0_67.
^ Weinreb O, Amit T, Bar-Am O, Youdim MB (2007). „Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy”. Annals of the New York Academy of Sciences. 1122 (1): 155—68. Bibcode:2007NYASA1122..155W. PMID 18077571. doi:10.1196/annals.1403.011.
^ Weinstock M, Poltyrev T, Bejar C, Youdim MB (2002). „Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression”. Psychopharmacology. 160 (3): 318—24. PMID 11889501. doi:10.1007/s00213-001-0978-x.
^ Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (2003). „A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease”. Progress in Neuro-psychopharmacology & Biological Psychiatry. 27 (4): 555—61. PMID 12787840. doi:10.1016/S0278-5846(03)00053-8.

Vidi još

Spoljašnje veze

[pmid11205137-1] Weinstock, M.; Bejar, C.; Wang, R. H.; et al. (2000). „TV3326, a novel neuroprotective drug with cholinesterase and monoamine oxidase inhibitory activities for the treatment of Alzheimer's disease”. Journal of Neural Transmission. Supplementum (60): 157—69. ISBN 978-3-211-83537-1. PMID 11205137. doi:10.1007/978-3-7091-6301-6_10.

[pmid19110207-2] Weinreb, O.; Mandel, S.; Bar-Am O; et al. (2009). „Multifunctional neuroprotective derivatives of rasagiline as anti-Alzheimer's disease drugs”. Neurotherapeutics : The Journal of the American Society for Experimental NeuroTherapeutics. 6 (1): 163—74. PMC 5084264 . PMID 19110207. doi:10.1016/j.nurt.2008.10.030.

[pmid17017566-3] Weinstock M, Luques L, Bejar C, Shoham S (2006). „Ladostigil, a novel multifunctional drug for the treatment of dementia co-morbid with depression”. Journal of Neural Transmission. Supplementum (70): 443—6. ISBN 978-3-211-28927-3. PMID 17017566. doi:10.1007/978-3-211-45295-0_67.

[pmid18077571-4] Weinreb O, Amit T, Bar-Am O, Youdim MB (2007). „Induction of neurotrophic factors GDNF and BDNF associated with the mechanism of neurorescue action of rasagiline and ladostigil: new insights and implications for therapy”. Annals of the New York Academy of Sciences. 1122 (1): 155—68. Bibcode:2007NYASA1122..155W. PMID 18077571. doi:10.1196/annals.1403.011.

[pmid11889501-5] Weinstock M, Poltyrev T, Bejar C, Youdim MB (2002). „Effect of TV3326, a novel monoamine-oxidase cholinesterase inhibitor, in rat models of anxiety and depression”. Psychopharmacology. 160 (3): 318—24. PMID 11889501. doi:10.1007/s00213-001-0978-x.

[pmid12787840-6] Weinstock M, Gorodetsky E, Poltyrev T, Gross A, Sagi Y, Youdim M (2003). „A novel cholinesterase and brain-selective monoamine oxidase inhibitor for the treatment of dementia comorbid with depression and Parkinson's disease”. Progress in Neuro-psychopharmacology & Biological Psychiatry. 27 (4): 555—61. PMID 12787840. doi:10.1016/S0278-5846(03)00053-8.

[1]